Introduction
Renal cell cancer is resistant to various chemotherapeutic agents. Although interferons are widely used for the treatment of renal cancer, the response rate is no more than 20% [1] . Even the combination of interferon-a with another anticancer drug or interferon-c only achieves about a 30% response rate [2, 13] . On the other hand, bladder cancer is generally thought to be sensitive to chemotherapy, but the results are not satisfactory.
It is known that the sensitivity to anticancer drugs diers between cancers even if they show the same histological ®ndings [4, 15] . There is a risk of tumor progression when anticancer drugs are not eective [6, 7] . Therefore, it may be important to make an eort to select the drug which will be eective, because it may produce a better result and improve the quality of life for individual cancer patients.
The Histoculture Drug Response Assay (HDRA) is an in vitro chemosensitivity test that was reported by Homan in 1991 [5] . The clinical ecacy of chemotherapy has been shown to have a strong correlation with HDRA data in various kinds of solid tumor [3, 4, 9] . However, there have been few reports on its use in urological cancer [11, 14] . In order to investigate the variation in chemosensitivity in urological cancers, we tested fresh biopsied or surgical specimens of bladder cancer and renal cell cancer with the HDRA. Chemotherapy was done on the basis of the HDRA results in some of the patients.
Materials and methods

Cancer samples
Cancer tissues were obtained during either surgical removal or biopsy at Hamamatsu University Hospital and related hospitals between August 1997 and March 1998. Informed consent for the chemosensitivity test was obtained from 45 patients before the procedure. Of the 45 specimens, 26 were bladder cancers and 19 were renal cell cancers. Twenty-four specimens of bladder cancer were histologically diagnosed as transitional cell cancer (TCC), of histological grade 1 in ®ve specimens, grade 2 in 12, and grade 3 in seven. The other two specimens were diagnosed as signet ring cell cancer and adenocarcinoma respectively; both arose from the urinary bladder. Renal cell cancers were grade 1 in six specimens, grade 2 in 10, and grade 3 in three.
Drugs
The medium used was RPMI 1640 medium (Nissui, Tokyo, Japan) supplemented with 20% heat-inactivated fetal bovine serum, 2 mM L-glutamine, and antibiotics (100 U/ml of penicillin and 100 lg/ml of streptomycin). Ten anticancer drugs were used: cisplatin (CDDP), carboplatin (CBDCA), 4-hydroxy-ifosfamide (4-H-IFO), methotrexate (MTX), vinblastine (VLB), 5-¯uorouracil (5-FU), mitomycin C (MMC), adriamycin (ADM), bleomycin (BLM), and etoposide (VP-16). Each drug was diluted in complete medium at 10 times therapeutic peak plasma concentration (10PPC) achieved by intravenous administration of clinical doses [12, 15] . The concentration of each drug was as follows: CDDP 20 lg/ml, CBDCA 250 lg/ml, 4-H-IFO 250 lg/ml, MTX 10 lg/ml, VLB 100 lg/ml, 5-FU 10 lg/ml, MMC 7.5 lg/ml, ADM 15 lg/ml, BLM 7 lg/ml, and VP-16 100 lg/ml.
4-H-IFO, which is the active form of ifosfamide, was kindly provided by Shionogi Pharmaceutical Company and the other nine drugs were purchased commercially. Collagen sponge gels were purchased from Yamanouchi Pharmaceutical (Tokyo, Japan). Although we tried to test all the drugs, this was not possible for all specimens because of the small volume of tissue obtained.
HDRA with MTT assay
The HDRA was performed as reported by Furukawa et al. [4] . Cancer tissue was identi®ed by the naked eye and cut into pieces approximately 2±3 mm in diameter using scissors. After weighing the individual pieces, they were placed on 1 cm cubes of collagen sponge gel in each well of a 24-well plate. Then each tumor piece was immersed in 800 ll of complete medium and 200 ll of an anticancer drug solution, followed by incubation at 37°C in a humidi®ed 5% CO 2 atmosphere for 7 days. Each drug was assessed in triplicate. Three tumor pieces incubated with 1000 ll of complete medium without any anticancer drug were used as controls for cell viability. After 7 days of incubation, 100 ll of RPMI 1640 containing 0.06% collagenase (type 1: Sigma) and 100 ll of 0.2% MTT (Sigma) solution were added to each well. The plate was then incubated for an additional 24 h. The supernatant in each well was aspirated carefully and 500 ll of dimethylsulfoxide (DMSO; Wako Pure Chemicals, Osaka, Japan) was added for solubilizing the MTT-formazan. After another 4 h of incubation, 100 ll of MTTformazan solution from each well was transferred to the wells of a 96-well microplate and the absorbance of each well was read on a microplate reader (Bio-Tek Instruments, USA) at a test wavelength of 550 nm. The inhibition rate (IR) was calculated as follows:
IR (%) = (1 A mean absorbance for drug-treated tumor per gram/mean absorbance for control tumor per gram)´100.
Microscopic examination
After 7 days of culture, a piece of each specimen incubated with 1000 ll of complete medium alone was observed under a microscope. Staining was done with hematoxylin-eosin and the ®ndings were compared with those before culture.
Clinical chemotherapy based on the HDRA Three bladder cancer patients with evaluable lesions received chemotherapy based on the results of the HDRA. Anticancer drugs which showed an IR value of more than 50% were selected. Before chemotherapy we obtained informed consent from all three patients.
Statistical analysis
The signi®cance of dierences between the IR values of bladder cancer and renal cell cancer were determined by an unpaired t-test. The relationship between the IR values of each anticancer drug and histological tumor grade was analyzed by one-factor ANOVA. A P value of less than 0.05 was considered to be statistically signi®cant.
Results
HDRA assessment of the samples
HDRA was possible for all of the bladder cancers (100%) and 17 of 19 (89.5%) renal cell cancers. Two renal cell cancer samples could not be assessed because they had a low optical density.
Microscopic ®ndings after the HDRA
The microscopic ®ndings of bladder cancer before and after the HDRA are shown in Fig. 1 . Cancer cells grew Cancer cells grew three-dimensionally with cell-to-cell contact, and tissue architecture was maintained on the collagen gels even after 7 days of culture three-dimensionally with cell-to-cell contact, and tissue architecture was maintained on the collagen gels even after 7 days of culture.
Comparison of inhibition rates between bladder cancer and renal cell cancer
The mean IR values of each drug for both cancers are shown in Table 1 . The IRs of CDDP, CBDCA, VLB, 5-FU, MMC, and ADM were signi®cantly higher for bladder cancer than renal cell cancer. The IRs of all other drugs were also higher for bladder cancer, although the dierences were not statistically signi®cant.
Relation between IR and histological grade
The relation between IR and histological grade is shown for VLB and 5-FU (Fig. 2) . Although high-grade bladder cancers tend to be less sensitive to drugs and highgrade renal cell cancers to be more sensitive, there was no signi®cant relationship between histological grade and IR for either drug or either cancer.
Distribution of IR values
The distributions of IR values are shown for MTX, VLB, and 4-H-IFO. Most cancers seemed to be rather resistant to MTX (Fig. 3) , while the other drugs showed a wide distribution of IR values. The distribution for VLB is shown in Fig. 3 as an example. On the whole, the chemosensitivity of renal cell cancer was lower than that of bladder cancer. Nevertheless, several renal cell cancer specimens showed a high sensitivity to certain drugs. Regarding the sensitivity to 4-H-IFO, renal cell cancer seems to be divided into sensitive and insensitive cancers (Fig. 3) . Clinical response of bladder cancer treated with drugs selected on the basis of the HDRA Three bladder cancer patients with evaluable lesions received chemotherapy using drugs selected on the basis of the results of the HDRA. Table 2 shows the clinical outcome of these three patients. Case 1 was a 65-yearold man with signet ring cell cancer. Since the cancer occupied the whole bladder and no distant metastasis was found, we recommended total cystectomy. However, he refused the cystectomy and asked for conservative treatment. We predicted that standard chemotherapy would not be eective, and performed intra-arterial infusion of CBDCA. After three courses of treatment tumor could not be identi®ed. After 12 months of follow-up, no recurrence and/or metastasis has been found.
Case 2 was an 84-year-old woman who presented to our hospital with gross hematuria and severe anemia.
Cystoscopy revealed widespread papillary, sessile, grade 2, and T3 transitional cell cancer. We selected bladderpreserving therapy because of her age. Intra-arterial infusion of CBDCA was performed. After three courses, tumor volume was reduced by more than 50%, and the gross hematuria was decreased. Eight months later, however, she died from cardiac failure.
Case 3 was a 70-year-old woman who had grade 2 transitional cell cancer of the bladder with metastases to the pelvic lymph nodes, liver, and lung. Based on the HDRA using the endoscopic biopsy specimen, she received one course of systemic chemotherapy with CDDP and 5-FU as the ®rst-line treatment. She was then given two courses of systemic chemotherapy with CDDP, VLB, and ADR. After the three courses of chemotherapy the metastatic lesions in the lung and pelvic lymph nodes disappeared and her bladder tumor was reduced in size. Twelve months later, she is still alive and has no symptoms. 
Discussion
In vitro chemosensitivity tests of solid cancer tissue have been performed using various methods [3±5, 7, 9, 11, 12, 14, 15] . Kondo et al. [7] reported the succinic dehydrogenase inhibition test (SDI method) in 1966. After that, Mossmann reported the MTT assay, which was a simpli®ed version of the SDI method [10] . The MTT assay used the tetrazolium salt, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), as an enzymatic receptor, the optical density being measured with a microplate reader [10] . This assay enabled the evaluation of chemosensitivity more rapidly and simply. The success rate was more than 90%. However, in this method the cancer cells are assessed as a single cell suspension and cell-to-cell contact is abolished [4] . Furthermore, most of the cells examined may actually be interstitial cells [4] , which are dicult to separate from cancer cells. Yamaue et al. [15] obtained good results for gastrointestinal tract cancer using a modi®ed MTT assay which included a process for removing interstitial cells.
The MTT assay has another weak point. Because drug contact time is only 72±96 h, it is considered to be too short for time-dependent drugs such as 5-FU [16] . Homan et al. [5] reported the HDRA utilizing a threedimensional culture system. In this method, approximately 1 mm 3 of cancer tissue is cultured on a collagen gel without enzymatic tissue digestion. Therefore, cellto-cell contact is maintained and long-term culture is possible under conditions resembling those in vivo, allowing cancer cells to remain alive for long enough to test 7 days of exposure to anticancer drugs. However, the original HDRA employed autoradiography [4] . In 1992, Furukawa et al. [4] reported an improved HDRA, which used the MTT assay to assess cell viability instead of autoradiography. His HDRA has already been used for gastric cancer, colorectal cancer, and other kinds of solid cancer [3, 4, 5, 9] . The results have con®rmed a strong correlation between the assay and the clinical response [3, 4, 5, 9] .
For urological cancers, a three-dimensional culture system was tried in the form of the collagen gel matrix assay by Uchibayashi et al. in 1993 [14] . They investigated six types of anticancer drugs in 40 specimens of cancer, including renal cell, urothelial, and prostatic cancer. Ogiwara et al. [11] also employed the collagen gel matrix assay to select the best anticancer drug for intra-arterial infusion chemotherapy in patients with bladder cancer. Although cancer tissues were cultured for 7 days on a collagen gel in both studies, the actual drug exposure time was only 3 days, which seems to be inadequate for predicting the eect of time-dependent drugs such as 5-FU or VLB. Yamaue et al. [16] compared the chemosensitivity of 100 samples of gastric cancer tissue to 5-FU between 72 h of drug exposure using the MTT assay and 7 days of drug exposure using the HDRA [16] . They found that chemosensitivity to 5-FU with 72 h drug exposure has the possibility of a higher false-positive rate [16] . That is the reason why we chose Furukawa's 7-day HDRA.
According to our results, the mean IRs for bladder cancer were higher than those for renal cell cancer, with a signi®cant dierence in CDDP, CBDCA, ADM, 5-FU, MMC, and VLB. These results are compatible with the clinical consensus that bladder cancer is comparatively sensitive and renal cell cancer is resistant to chemotherapy.
This study also revealed a wide distribution of chemosensitivity among cancers, even in bladder cancers. Regarding the data for 4-H-IFO, it suggested that, for this particular drug, individual cancers could be divided in two groups: sensitive and insensitive. Drug sensitivity is independent of the histological grade and therefore a chemosensitivity test for individual cancer cells is necessary to enable the choice of the appropriate therapeutic anticancer drug. The HDRA has been used for gastrointestinal cancers and Kubota et al. [9] reported that both the overall and disease-free survival rates of HDRAsensitive gastric cancer patients were signi®cantly higher than those of the HDRA-resistant group. For bladder cancer, MVAC therapy achieves a comparatively high response rate of approximately 50±60% [8] , but the remaining 40±50% patients do not show enough response although they suer from severe and harmful side eects.
Based on the results of the HDRA, we performed chemotherapy in three patients. One of the patients showed a complete response to intra-arterial therapy with a single eective anticancer drug. The other two patients showed a partial response. Although chemotherapy was not curative, their symptoms improved and quality of life was maintained.
In conclusion, this study has con®rmed that renal cell cancer, in general, is refractory to chemotherapy. However, HDRA can ®nd a eective drug even for these cancers. There is a wide variation in chemosensitivity among cancers of the same histological classi®cation. Therefore, the HDRA might be a feasible and a useful technique for predicting ecacy and selecting the appropraite anticancer drug for individual patients.
